{"disease":{"id":"palb2-gene-mutation","name":"palb2 gene mutation"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02993068","title":"Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)","phase":"NA","overall_status":"SUSPENDED","enrollment_count":5200,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT05420064","title":"An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT02760849","title":"Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutations","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":374,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT02286687","title":"Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03344965","title":"Olaparib In Metastatic Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":114,"lead_sponsor_name":"Beth Israel Deaconess Medical Center","has_results":false},{"nct_id":"NCT04584255","title":"Niraparib + Dostarlimab In BRCA Mutated Breast Cancer","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":62,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT03377556","title":"Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":true},{"nct_id":"NCT05097274","title":"The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.","phase":"","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Institute of Cancer Research, United Kingdom","has_results":false},{"nct_id":"NCT05694715","title":"Combination Therapy in Cancers With Mutations in DNA Repair Genes","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06177171","title":"Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":18,"lead_sponsor_name":"Pamela Munster","has_results":false},{"nct_id":"NCT06783140","title":"Study of NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Pancreatic Cancer","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"University Health Network, Toronto","has_results":false}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}